We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New Perspectives about Drug Candidates Targeting HTLV-1 and Related Diseases.
- Authors
Silva, Milena Cristina Martins da; Pereira, Renan Stefferson Barradas; Araujo, Antonia Cherlly Aparecida; Filho, Ednilson Gregorio da Silva; Dias, Anderson de Lima; Cavalcante, Kassio Silva; Sousa, Maísa Silva de
- Abstract
Among the human T-lymphotropic virus (HTLV) types, HTLV-1 is the most prevalent, and it has been linked to a spectrum of diseases, including HAM/TSP, ATLL, and hyperinfection syndrome or disseminated strongyloidiasis. There is currently no globally standard first-line treatment for HTLV-1 infection and its related diseases. To address this, a comprehensive review was conducted, analyzing 30 recent papers from databases PubMed, CAPES journals, and the Virtual Health Library (VHL). The studies encompassed a wide range of therapeutic approaches, including antiretrovirals, immunomodulators, antineoplastics, amino acids, antiparasitics, and even natural products and plant extracts. Notably, the category with the highest number of articles was related to drugs for the treatment of ATLL. Studies employing mogamulizumab as a new perspective for ATLL received greater attention in the last 5 years, demonstrating efficacy, safe use in the elderly, significant antitumor activity, and increased survival time for refractory patients. Concerning HAM/TSP, despite corticosteroid being recommended, a more randomized clinical trial is needed to support treatment other than corticoids. The study also included a comprehensive review of the drugs used to treat disseminated strongyloidiasis in co-infection with HTLV-1, including their administration form, in order to emphasize gaps and facilitate the development of other studies aiming at better-directed methodologies. Additionally, docking molecules and computer simulations show promise in identifying novel therapeutic targets and repurposing existing drugs. These advances are crucial in developing more effective and targeted treatments against HTLV-1 and its related diseases.
- Subjects
HTLV; DRUG target; MOLECULAR docking; THERAPEUTICS; CLINICAL trials; ANTIPARASITIC agents
- Publication
Pharmaceuticals (14248247), 2023, Vol 16, Issue 11, p1546
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph16111546